Show simple item record

dc.contributor.authorBrojer, Eva
dc.contributor.authorHusebekk, Anne
dc.contributor.authorDebska, Marzena
dc.contributor.authorUhrynowska, Malgorozata
dc.contributor.authorGuz, Katarzyna
dc.contributor.authorOrzinska, Agnieszka
dc.contributor.authorDebski, Romuald
dc.contributor.authorMaslanka, Krystyna
dc.date.accessioned2016-03-14T13:31:32Z
dc.date.available2016-03-14T13:31:32Z
dc.date.issued2015-11-12
dc.description.abstractFetal/neonatal alloimmune thrombocytopenia (FNAIT) is a relatively rare condition (1/1000–1/2000) that was granted orphan status by the European Medicines Agency in 2011. Clinical consequences of FNAIT, however, may be severe. A thrombocytopenic fetus or new-born is at risk of intracranial hemorrhage that may result in lifelong disability or death. Preventing such bleeding is thus vital and requires a solution. Anti-HPA1a antibodies are the most frequent cause of FNAIT in Caucasians. Its pathogenesis is similar to hemolytic disease of the newborn (HDN) due to anti-RhD antibodies, but is characterized by platelet destruction and is more often observed in the first pregnancy. In 75 % of these women, alloimmunization by HPA-1a antigens, however, occurs at delivery, which enables development of antibody-mediated immune suppression to prevent maternal immunization. As for HDN, the recurrence rate of FNAIT is high. For advancing diagnostic efforts and treatment, it is thereby crucial to understand the pathogenesis of FNAIT, including cellular immunity involvement. This review presents the current knowledge on FNAIT. Also described is a program for HPA-1a screening in identifying HPA-1a negative pregnant women at risk of immunization. This program is now performed at the Institute of Hematology and Transfusion Medicine in cooperation with the Department of Obstetrics and Gynecology of the Medical Centre of Postgraduate Education in Warsaw as well as the UiT The Arctic University of Norway.en_US
dc.descriptionPublished version. Source at <a href=http://doi.org/10.1007/s00005-015-0371-9>http://doi.org/10.1007/s00005-015-0371-9</a>.en_US
dc.identifier.citationArchivum Immunologiae et Therapiae Experimentalis 2015en_US
dc.identifier.cristinIDFRIDAID 1326206
dc.identifier.doi10.1007/s00005-015-0371-9
dc.identifier.issn0004-069X
dc.identifier.urihttps://hdl.handle.net/10037/8935
dc.identifier.urnURN:NBN:no-uit_munin_8484
dc.language.isoengen_US
dc.publisherSpringeren_US
dc.rights.accessRightsopenAccess
dc.subjectHuman platelet alloantigensen_US
dc.subjectPregnancyen_US
dc.subjectFetal/neonatal alloimmune thrombocytopeniaen_US
dc.subjectTherapeutic interventionen_US
dc.subjectVDP::Medisinske Fag: 700::Helsefag: 800en_US
dc.titleFetal/Neonatal Alloimmune Thrombocytopenia: Pathogenesis, Diagnostics and Preventionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record